Tags

Type your tag names separated by a space and hit enter

Safety and efficacy of tamsulosin, alfuzosin or silodosin as monotherapy for LUTS in BPH - a double-blind randomized trial.
Cent European J Urol. 2017 Jun 30; 70(2):148-153.CE

Abstract

INTRODUCTION

Currently alpha1-adrenoceptor blockers (AB) are widely used as first-line therapy to improve lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). We compared the efficacy and safety profile of tamsulosin, alfuzosin and silodosin in LUTS due to BPH.

MATERIAL AND METHODS

Consecutive consenting male patients (N = 269) undergoing medical management of BPH with AB from February 2012 to October 2015 were enrolled. Patients were randomized to a 0.4 mg tamsulosin (group T), 10 mg alfuzosin (group A) or a 8 mg silodosin (group S) by double-blind randomization. All patients were assessed for improvements and post-void residual urine (PVR) and for adverse drug events (ADE).

RESULTS

IPSS showed significant improvement in Group S at the first week (11.7 ±4.18, p = 0.027) and at 3 months (7.97 ±3.84, p = 0.020). QOL showed significant improvement at 1 (2.2 ±0.76, p = 0.020), 4 (1.47 ±0.63, p <0.001) and 12 (1.2 ±0.66, p <0.001) weeks in Group S. The mean Qmax improvement was the maximum (13.76 ±2.44, p = 0.028) in Group S at 1 week. Reduction in PVR was the maximum in Group S, but it was not statistically significant. Adverse drug events (ADE) were observed in 20.07% (54/269) patients and distribution was similar in the three groups with decreasing incidence with progression of time.

CONCLUSIONS

Silodosin is the most efficacious AB with rapid onset of action. Silodosin also improves the quality of life in patients with LUTS due to BPH and objectively improves maximum flow rate. However, silodosin has more adverse events when compared to tamsulosin and alfuzosin.

Authors+Show Affiliations

Insititute of Nephro Urology, Bangalore, India.Insititute of Nephro Urology, Bangalore, India.Insititute of Nephro Urology, Bangalore, India.Insititute of Nephro Urology, Bangalore, India.Insititute of Nephro Urology, Bangalore, India.Insititute of Nephro Urology, Bangalore, India.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

28721281

Citation

Manohar, Chikka Moga Siddaiah, et al. "Safety and Efficacy of Tamsulosin, Alfuzosin or Silodosin as Monotherapy for LUTS in BPH - a Double-blind Randomized Trial." Central European Journal of Urology, vol. 70, no. 2, 2017, pp. 148-153.
Manohar CMS, Nagabhushana M, Karthikeyan VS, et al. Safety and efficacy of tamsulosin, alfuzosin or silodosin as monotherapy for LUTS in BPH - a double-blind randomized trial. Cent European J Urol. 2017;70(2):148-153.
Manohar, C. M. S., Nagabhushana, M., Karthikeyan, V. S., Sanjay, R. P., Kamath, A. J., & Keshavamurthy, R. (2017). Safety and efficacy of tamsulosin, alfuzosin or silodosin as monotherapy for LUTS in BPH - a double-blind randomized trial. Central European Journal of Urology, 70(2), 148-153. https://doi.org/10.5173/ceju.2017.924
Manohar CMS, et al. Safety and Efficacy of Tamsulosin, Alfuzosin or Silodosin as Monotherapy for LUTS in BPH - a Double-blind Randomized Trial. Cent European J Urol. 2017 Jun 30;70(2):148-153. PubMed PMID: 28721281.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Safety and efficacy of tamsulosin, alfuzosin or silodosin as monotherapy for LUTS in BPH - a double-blind randomized trial. AU - Manohar,Chikka Moga Siddaiah, AU - Nagabhushana,Mahadevappa, AU - Karthikeyan,Vilvapathy Senguttuvan, AU - Sanjay,Ramachandra Pudakalkatti, AU - Kamath,Ananth Janardhan, AU - Keshavamurthy,Ramaiah, Y1 - 2017/06/07/ PY - 2016/10/11/received PY - 2016/12/08/revised PY - 2017/02/05/accepted PY - 2017/7/20/entrez PY - 2017/7/20/pubmed PY - 2017/7/20/medline KW - alfuzosin KW - alpha 1-adrenoceptor blocker KW - benign prostatic hyperplasia KW - silodosin KW - tamsulosin SP - 148 EP - 153 JF - Central European journal of urology JO - Cent European J Urol VL - 70 IS - 2 N2 - INTRODUCTION: Currently alpha1-adrenoceptor blockers (AB) are widely used as first-line therapy to improve lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). We compared the efficacy and safety profile of tamsulosin, alfuzosin and silodosin in LUTS due to BPH. MATERIAL AND METHODS: Consecutive consenting male patients (N = 269) undergoing medical management of BPH with AB from February 2012 to October 2015 were enrolled. Patients were randomized to a 0.4 mg tamsulosin (group T), 10 mg alfuzosin (group A) or a 8 mg silodosin (group S) by double-blind randomization. All patients were assessed for improvements and post-void residual urine (PVR) and for adverse drug events (ADE). RESULTS: IPSS showed significant improvement in Group S at the first week (11.7 ±4.18, p = 0.027) and at 3 months (7.97 ±3.84, p = 0.020). QOL showed significant improvement at 1 (2.2 ±0.76, p = 0.020), 4 (1.47 ±0.63, p <0.001) and 12 (1.2 ±0.66, p <0.001) weeks in Group S. The mean Qmax improvement was the maximum (13.76 ±2.44, p = 0.028) in Group S at 1 week. Reduction in PVR was the maximum in Group S, but it was not statistically significant. Adverse drug events (ADE) were observed in 20.07% (54/269) patients and distribution was similar in the three groups with decreasing incidence with progression of time. CONCLUSIONS: Silodosin is the most efficacious AB with rapid onset of action. Silodosin also improves the quality of life in patients with LUTS due to BPH and objectively improves maximum flow rate. However, silodosin has more adverse events when compared to tamsulosin and alfuzosin. SN - 2080-4806 UR - https://www.unboundmedicine.com/medline/citation/28721281/Safety_and_efficacy_of_tamsulosin_alfuzosin_or_silodosin_as_monotherapy_for_LUTS_in_BPH___a_double_blind_randomized_trial_ L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/28721281/ DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.